Please assess the completion status of the following clinical trial:

Trial Title: Chronotherapy in Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Above the ages of 18~* Diagnosis of Crohn's Disease or Ulcerative Colitis~* Currently taking azathioprine or 6-mercaptopurine~* Willing to sign study consent form~Exclusion Criteria:~* Vulnerable population (pregnant, prisoner, non-English speaking or cognitively impaired)~* Breastfeeding subject~* Have a history of complications related to immunomodulatory therapy~* Participating in other research studies involving research interventions~* Treated with dual corticosteroid and immunomodulatory therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morning (Type: EXPERIMENTAL): Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the evening were assigned to the morning group. Instead of taking their medication at their usual PM time, they were instructed to take their medications in the morning for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.
- Evening (Type: EXPERIMENTAL): Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the morning were assigned to the evening group. Instead of taking their medication at their usual AM time, they were instructed to take their medications in the evening for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).